Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.
The potential of vaccine-elicited anti-HIV envelope antibodies to control HIV-infection was evaluated by immunizing macaques with the HIV envelope protein and transiently depleting them of their CD8+ cells before intravenous challenge with the pathogenic CCR5-tropic SIV/HIV chimeric virus, SHIV(SF162P4). Although sterilizing immunity was not achieved, all vaccinated animals effectively controlled infection and remained free of disease for the duration of observation (over 3 years). In contrast, during the same period, the control animals progressed to disease. Both the vaccinees and the controls developed robust cell-mediated antiviral and neutralizing antibody responses following infection. A comparative analysis of these responses suggests that the more effective long-term control of infection by the vaccinated animals is due to the more rapid development of anti-HIV envelope antibodies. These studies suggest that priming by vaccination of B cell anti-HIV envelope responses maybe crucial for the long-term control of HIV infection.
Buckner
Clarisa
C
Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA.
Gines
Leoned G
LG
Saunders
Cheryl J
CJ
Vojtech
Lucia
L
Srivastava
Indresh
I
Gettie
Agegnehu
A
Bohm
Rudolph
R
Blanchard
James
J
Barnett
Susan W
SW
Safrit
Jeffrey T
JT
Stamatatos
Leonidas
L
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D006023:Glycoproteins / Q000276:immunology*; D015483:HIV Antibodies / Q000032:analysis / Q000097:blood; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D007110:Immunity, Active; D008253:Macaca mulatta; D019713:Receptors, CCR5 / Q000378:metabolism; D011995:Recombination, Genetic; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000378:metabolism; D013997:Time Factors; D014611:Vaccination; D022223:Vaccines, Subunit / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*
D016915:AIDS Vaccines; C033904:GP 140; D006023:Glycoproteins; D015483:HIV Antibodies; D019713:Receptors, CCR5; D022223:Vaccines, Subunit; D014759:Viral Envelope Proteins